Valuation : Atara Biotherapeutics, Inc.

Market Cap 94.76M 81.53M 76.51M 70M 131M 8.96B 132M 905M 352M 4.58B 356M 348M 14.74B P/E 2026 *
-9.54x
P/E 2027 * 7.96x
Enterprise Value 94.76M 81.53M 76.51M 70M 131M 8.96B 132M 905M 352M 4.58B 356M 348M 14.74B EV / Sales 2026 *
33.3x
EV / Sales 2027 * 2.32x
Free-Float
84.86%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week+1.62%
Current month+5.62%
1 month+9.94%
3 months-2.39%
6 months+73.43%
Current year-48.04%
1 week 8.8
Extreme 8.8
9.49
1 month 7.73
Extreme 7.73
10.02
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
49
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-08
Director of Finance/CFO 61 2026-06-25
Investor Relations Contact - 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-02-28
Director/Board Member 66 2015-11-22
Director/Board Member 53 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
5/18/26 Sell

Controller/Auditor

-2,414 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+1.62%-25.57%-75.10% 94.76M
+1.03%-2.05%+39.28%+94.60% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.20%+3.28%-12.63%+375.45% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.84%-7.74%+2.35%-15.75% 26.08B
+1.01%+1.38%+26.48%-17.50% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+0.88%+7.08%+60.11%+165.72% 14.5B
Average +1.07%-2.33%+40.73%+157.20% 28.04B
Weighted average by Cap. +1.13%-2.12%+42.89%+141.66%

Financials

2026 *2027 *
Net sales 2.85M 2.45M 2.3M 2.1M 3.93M 269M 3.96M 27.21M 10.6M 138M 10.7M 10.46M 443M 40.87M 35.16M 33M 30.19M 56.35M 3.86B 56.79M 390M 152M 1.97B 153M 150M 6.36B
Net income -14.62M -12.58M -11.8M -10.8M -20.16M -1.38B -20.32M -140M -54.38M -706M -54.9M -53.7M -2.27B 18.66M 16.05M 15.06M 13.78M 25.72M 1.76B 25.93M 178M 69.39M 901M 70.06M 68.53M 2.9B
Net Debt - -
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
26-09-03 US$9.400 -0.42% 19,277
26-09-02 US$9.440 +4.66% 20,898
26-09-01 US$9.020 +1.35% 51,945
26-08-31 US$8.900 -3.26% 30,242
26-08-28 US$9.200 -0.54% 15,345
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.440USD
Average target price
13.67USD
Spread / Average Target
+44.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATRA Stock